ACAD Earnings

ACAD reported its earnings on 2026-02-25, showcasing a revenue of against an estimate of 292.58M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.12 by 0%. The stock experienced a -1.32% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ACAD's earnings announcement on 2026-02-25, the stock price moved by -1.32% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ACAD's stock price tends to shift by an average of -1.56% in the 10 days leading up to earnings and -1.77% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ACAD's annual revenue to reach 283.10M, while the EPS is projected at 0.12. These estimates reflect recent revisions, with revenue estimates revised downward by -0.01% and EPS estimates revised downward by -0.02% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ACAD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.01%, while EPS estimates moved revised downward by -0.02%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ACAD's stock price typically moves by -1.56% in the 10 days before its earnings and -1.77% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.12 and revenue of 283.10M.

The earnings call summary presents a mixed picture: strong revenue growth and optimistic guidance, particularly for NUPLAZID, contrast with increased R&D and SG&A expenses. The absence of a share repurchase program and unresolved regulatory and competitive challenges add uncertainty. The Q&A section reveals confidence in future pricing and product success, but also highlights risks in regulatory approval and market competition. Given the market cap of approximately $2.7 billion, the overall sentiment suggests a neutral stock price movement in the near term.